Naim Alkhouri

6 days ago | ajmc.com | Kyle Munz |Naim Alkhouri

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.

1 week ago | ajmc.com | Kyle Munz |Naim Alkhouri

In a previous installment of his interview with The American Journal of Managed Care®, (AJMC®), Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health pointed to one of the primary obstacles impeding progress in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): awareness.

3 weeks ago | ajmc.com | Kyle Munz |Naim Alkhouri

By the end of this decade, patients with metabolic dysfunction–associated steatohepatitis (MASH) cirrhosis could have their first approved treatment, explained Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver program, Arizona Liver Health.

4 weeks ago | ajmc.com | Kyle Munz |Naim Alkhouri

Over the past decade, the treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has undergone significant transformation, explained Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health.

Nov 27, 2024 | healio.com | Kate Burba |Naim Alkhouri |Monica Stonehill

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Agile 3+ correctly identified more patients at high risk for MASH (55% vs. 33%). FAST misclassified fewer patients as having low risk MASH among those with stage 2 and 3 fibrosis.